# Zymfentra (Infliximab-dyyb) REal World Cohort STudy

> **NCT07237516** · — · RECRUITING · sponsor: **University of North Carolina, Chapel Hill** · enrollment: 200 (estimated)

## Conditions studied

- Ulcerative Colitis (UC)
- Crohn's Disease (CD)
- Indeterminate Colitis
- Inflammatory Bowel Disease (IBD)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07237516
- **Lead sponsor:** University of North Carolina, Chapel Hill
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-20
- **Primary completion:** 2028-11-03
- **Final completion:** 2028-11-03
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07237516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07237516, "Zymfentra (Infliximab-dyyb) REal World Cohort STudy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07237516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*